Low Grade NH Lymphoma (General NHL, FL, WM)
cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (CHOP) Therapy– 21 days
Chlorambucil 10mg/m2 Therapy
riTUXimab and Bendamustine Therapy
Indication
00345a
Treatment of patients with previously untreated indolent CD20-positive, stage III-IV Non-Hodgkin lymphoma (NHL).
R-CEOP Therapy -21 days
Indication
00510a
Treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy
(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP Therapy– 14 days
Indication
00409a
Treatment of Non-Hodgkin Lymphoma (NHL)*
*riTUXimab to be included in CD20 positive patients
(*riTUXimab) cycloPHOSphamide, DOXOrubicin, VinCRIStine and prednisoLONE (*R)-CHOP) Therapy– 21 days
Indication
00307a
Treatment of Non-Hodgkin Lymphoma (NHL).*
*riTUXimab to be included in CD20 positive patients.
riTUXimab S/C, cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (R-CHOP) Therapy – 21 Days
(R**)- miniCHOP Therapy – 21 days
Indication
00436a
Treatment of Non-Hodgkin Lymphoma in patients aged greater than 80 or with significant co-morbidities.
* riTUXimab to be included in all CD20 positive patients.
(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient
(R*)-ESHAP Therapy
riTUXimab** Gemcitabine and CISplatin ((R**)-GDP) Therapy
(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy
Indication
00397a
Treatment of relapsed/refractory Non-Hodgkin Lymphoma**
**riTUXimab to be included in CD20 positive patients.
ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy
(*riTUXimab) CycloPHOSphamide and prednisoLONE (R*)-CVP ) Therapy-21 days
Indication
00293b
Treatment of patients with relapsed/refractory low grade B cell Non-Hodgkin lymphoma (NHL)*
*riTUXimab to be included in CD20 positive patients.
riTUXimab 375 mg/m2 Maintenance Therapy-84 day
Indication
00540a
Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell Non-Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy
riTUXimab 375 mg/m2 Maintenance Therapy- 56 day
Indication
00543a
Maintenance therapy for the treatment of previously untreated follicular CD20 positive, B-cell Non-Hodgkin Lymphoma patients responding to induction therapy
riTUXimab (S/C 1400mg) Maintenance Therapy-84 day
Indication
00599a
Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell Non-Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy
riTUXimab (S/C 1400mg) Maintenance Therapy- 56 day
Indication
00600a
Maintenance therapy for the treatment of previously untreated follicular CD20 positive, B-cell Non-Hodgkin Lymphoma patients responding to induction therapy
ESHAP Therapy
Idelalisib Monotherapy
Indication
00291a
Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
Obinutuzumab Maintenance Therapy - 56 day
Indication
00425a
Obinutuzumab maintenance therapy is indicated in patients with follicular lymphoma (FL) who have responded to induction treatment with obinutuzumab and chemotherapy (CHOP, CVP or bendamustine) or have stable disease.
Obinutuzumab and Bendamustine Therapy
Indication
00424a
Obinutuzumab in combination with bendamustine is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with riTUXimab or a riTUXimab-containing regimen.
00424b
Obinutuzumab in combination with bendamustine is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.
Obinutuzumab cycloPHOSphamide vinCRIStine and prednisoLONE (O- CVP) Therapy– 21 days
Indication
00550a
Obinutuzumab in combination with CVP chemotherapy is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.
Obinutuzumab and cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (O-CHOP) Therapy – 21 day
Indication
00549a
Obinutuzumab in combination with CHOP chemotherapy is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.
riTUXimab 375 mg/m2 Therapy-7 day
Indication
00541a
First line treatment of follicular lymphoma
00541b
As monotherapy for induction treatment for adult patients with stage
III-IV follicular lymphoma who are chemoresistant or are in their second
or subsequent relapse after chemotherapy
00541c
As monotherapy for retreatment of patients who have responded to
previous treatment with riTUXimab monotherapy for
relapsed/refractory follicular lymphoma
riTUXimab 375 mg/m2 Combination Therapy-21 day
Indication
00542a
In combination with chemotherapy for induction treatment of
previously untreated or relapsed/ refractory CD 20 positive patients
with follicular lymphoma
(*riTUXimab) cycloPHOSphamide and prednisoLONE (R*)-CVP ) Therapy-21 days
dexAMETHasone, riTUXimab and cycloPHOSphamide (DRC) Therapy
Indication
00532a
Treatment of symptomatic treatment naive or relapsed/refractory Waldenstrom’s macroglobulinaemia
Ibrutinib Therapy-CLL Waldenström’s macroglobulinaemia
Indication
00296c
As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
Zanubrutinib Therapy
Indication
00708a
As monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM), who have received at least one prior therapy or as first line treatment for patients unsuitable for chemo-immunotherapy